Find out how different vaccines for the coronavirus cause your body to create antibodies that fight the virus.

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

Shah Capital renews pressure on Novavax board, saying the biotech’s underperformance calls for a strategic sale to unlock ...

New and changing FDA and CDC guidance on COVID-19 vaccine eligibility has left many confused. Here's what to know about ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. Novavax, Inc. (NASDAQ:NVAX ...

Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million. | Novavax will remain headquartered at ...

Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing ...

Under pre-Trump administration U.S. policy, COVID shots were authorized and recommended for all Americans ages 6 months or older. That’s over. Seniors and people with high-risk health conditions can ...

GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid ™ 2025-2026 Formula for the ...

The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...